The expanding spectrum of the autoimmune lymphoproliferative syndromes

Current Opinion in Pediatrics

Volumn 25, Issue 6, 2013, Pages 722-729

  Oliveira, João Bosco ^a  

^a INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

Author keywords

apoptosis; autoimmune lymphoproliferative syndrome; genetics; PRKCD; RAS

Indexed keywords

ANTINUCLEAR ANTIBODY; CASPASE 8; K RAS PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN KINASE C; PROTEIN KINASE C DELTA; STEROID;

APOPTOSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; AUTOSOMAL DOMINANT INHERITANCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOPENIA; DISEASE SEVERITY; GENE EXPRESSION; GENERALIZED LYMPHADENOPATHY; GENETICS; GLOMERULOPATHY; HEPATOSPLENOMEGALY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOCYTE PROLIFERATION; MONOGENIC DISORDER; MUTATION; NATURAL KILLER CELL; NEUTROPENIA; NONHUMAN; NORMOCHROMIC NORMOCYTIC ANEMIA; PATHOPHYSIOLOGY; PENETRANCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOMATIC MUTATION; SPLENOMEGALY; VASCULITIS;

APOPTOSIS; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNITY; CELL PROLIFERATION; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FEMALE; GENES, RAS; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; MALE; MUTATION; PROTEIN KINASE C-DELTA; SIGNAL TRANSDUCTION;

EID: 84888129924     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0000000000000032     Document Type: Review

References (57)

1. Lenardo M, Chan KM, Hornung F, et al. Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999; 17:221-253.
2. Bidere N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 2006; 24:321-352.
3. Sneller MC, Wang J, Dale JK, et al. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997; 89:1341-1348.
4. Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood 2010; 116:e35-e40.
5. Neven B, Magerus-Chatinet A, Florkin B, et al. A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood 2011; 118:4798-4807.
6. Bleesing JJ, Brown MR, Straus SE, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood 2001;98:2466-2473.
7. Bleesing JJ, Brown MR, Dale JK, et al. TcR-alpha/beta() CD4(-)CD8(-) T cells in humans with the autoimmune lymphoproliferative syndrome express a novel CD45 isoform that is analogous to murine B220 and represents a marker of altered O-glycan biosynthesis. Clin Immunol 2001; 100:314-324.
8. Kwon SW, Procter J, Dale JK, et al. Neutrophil and platelet antibodies in autoimmune lymphoproliferative syndrome. Vox Sang 2003; 85:307-312.
9. Stroncek DF, Carter LB, Procter JL, et al. RBC autoantibodies in autoimmune lymphoproliferative syndrome. Transfusion 2001; 41:18-23.
10. Caminha I, Fleisher TA, Hornung RL, et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol 2010; 125:946-949; e946.
11. Magerus-Chatinet A, Stolzenberg MC, Loffredo MS, et al. FAS-L, IL-10, and double-negative CD4-CD8-TCR alpha/beta T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. Blood 2009; 113:3027-3030.
12. Dowdell KC, Niemela JE, Price S, et al. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood 2010; 115:5164-5169.
13. Lim MS, Straus SE, Dale JK, et al. Pathological findings in human autoimmune lymphoproliferative syndrome. Am J Pathol 1998; 153:1541-1550.
14. Maric I, Pittaluga S, Dale JK, et al. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am J Surg Pathol 2005; 29:903-911.
15. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001; 98:194-200.
16. Kuehn HS, Caminha I, Niemela JE, et al. FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome. J Immunol 2011; 186:6035-6043.
17. Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol 1994; 24:3057-3062.
18. Teachey DT. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome. Curr Opin Pediatr 2012; 24:1-8.
19. Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288:2354-2357.
20. Wang L, Yang JK, Kabaleeswaran V, et al. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat Struct Mol Biol 2010; 17:1324-1329.
21. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-1349.
22. Hsu AP, Dowdell KC, Davis J, et al. Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance. Genet Med 2012; 14:81-89.
23. Magerus-Chatinet A, Neven B, Stolzenberg MC, et al. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. J Clin Invest 2011; 121:106-112.
24. Hauck F, Magerus-Chatinet A, Vicca S, et al. Somatic loss of heterozygosity, but not haploinsufficiency alone, leads to full-blown autoimmune lymphoproliferative syndrome in 1 of 12 family members with FAS start codon mutation. Clin Immunol 2013; 147:61-68.
25. Holzelova E, Vonarbourg C, Stolzenberg MC, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 2004;351:1409-1418.
26. Zhu S, Hsu AP, Vacek MM, et al. Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome. Hum Genet 2006; 119:284-294.
27. Wang J, Zheng L, Lobito A, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999; 98:47-58.
28. Wu J, Wilson J, He J, et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-1113.
29. Del-Rey M, Ruiz-Contreras J, Bosque A, et al. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. Blood 2006; 108:1306-1312.
30. Bi LL, Pan G, Atkinson TP, et al. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib. BMC Med Genet 2007; 8:41.
31. Magerus-Chatinet A, Stolzenberg MC, Lanzarotti N, et al. Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. J Allergy Clin Immunol 2013; 131:486-490.
32. Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood 2011; 118:5741-5751.
33. Rao VK, Dugan F, Dale JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005; 129:534-538.
34. Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 2009; 145:101-106.
35. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet 1999; 64:1002-1014.
36. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic lymphocyte activation defects due to caspase-8 mutation cause human immunodeficiency. Nature 2002;419:395-399.
37. Salmena L, Hakem R. Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder. J Exp Med 2005; 202:727-732.
38. Su H, Bidere N, Zheng L, et al. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 2005; 307:1465-1468.
39. Bidere N, Snow AL, Sakai K, et al. Caspase-8 regulation by direct interaction with TRAF6 in T cell receptor-induced NF-kappaB activation. Curr Biol 2006;16:1666-1671.
40. Bolze A, Byun M, McDonald D, et al. Whole-exome-sequencing-based discovery of human FADD deficiency. Am J Hum Genet 2010; 87:873-881.
41. Park SM, Schickel R, Peter ME. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr Opin Cell Biol 2005;17:610-616.
42. Balachandran S, Venkataraman T, Fisher PB, Barber GN. Fas-associated death domain-containing protein-mediated antiviral innate immune signaling involves the regulation of Irf7. J Immunol 2007; 178:2429-2439.
43. Niemela JE, Lu L, Fleisher TA, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood 2011; 117:2883-2886.
44. Oliveira JB, Bidere N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci U S A 2007;104:8953-8958.
45. Takagi M, Shinoda K, Piao J, et al. Autoimmune lymphoproliferative syndromelike disease with somatic KRAS mutation. Blood 2011; 117:2887-2890.
46. de Vos AM, Tong L, Milburn MV, et al. Three-dimensional structure of an oncogene protein: catalytic domain of human c-H-ras p21. Science 1988;239:888-893.
47. O'Reilly LA, Kruse EA, Puthalakath H, et al. MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation. J Immunol 2009; 183:261-269.
48. Ley R, Ewings KE, Hadfield K, Cook SJ. Regulatory phosphorylation of Bim: sorting out the ERK from the JNK. Cell Death Differ 2005; 12:1008-1014.
49. Limnander A, Weiss A. Ca-dependent Ras/Erk signaling mediates negative selection of autoreactive B cells. Small GTPases 2011; 2:282-288.
50. Limnander A, Depeille P, Freedman TS, et al. STIM1, PKC-delta and RasGRP set a threshold for proapoptotic Erk signaling during B cell development. Nat Immunol 2011; 12:425-433.
51. Kuehn HS, Niemela JE, Rangel-Santos A, et al. Loss-of-function of the protein kinase C delta (PKCdelta) causes a B-cell lymphoproliferative syndrome in humans. Blood 2013; 21:3117-3125.
52. Salzer E, Santos-Valente E, Klaver S, et al. B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C delta. Blood 2013;121:3112-3116
53. Miyamoto A, Nakayama K, Imaki H, et al. Increased proliferation of B cells and auto-immunity in mice lacking protein kinase Cdelta. Nature 2002; 416:865-869.
54. Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature 1984; 312:315-321.
55. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258:607-614.
56. Fujii T, Garcia-Bermejo ML, Bernabo JL, et al. Involvement of protein kinase C delta (PKCdelta) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCdelta. J Biol Chem 2000;275:7574-7582.
57. Guo B, Su TT, Rawlings DJ. Protein kinase C family functions in B-cell activation. Curr Opin Immunol 2004; 16:367-373.